Concepedia

Author

Cheng Huang

Fujian Provincial Cancer HospitalORCID

Also Known As

C Huang, C. Huang, Caisheng Huang, Caiyin Huang, Changmin HUANG, Chein-Yu Huang, Cheng Huang, Chenghe Huang, HUANG Cheng, Huang C

194

Publications

5.9K

Citations

38

H-Index

71

Concepts

All Affiliations

Fujian Provincial Cancer HospitalPeking UniversityJilin Province Tumor HospitalZhejiang Cancer HospitalJiangsu Cancer Hospital
CH

About

Cheng Huang is an author at Fujian Provincial Cancer Hospital specializing in medicine, oncology, and lung cancer.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

30

48

4K

2

Health Sciences

14

15

950

3

Anesthesia

5

5

344

4

Social Sciences

4

4

190

5

Engineering

1

1

26

Cheng Huang

×

79

Publications

5.5K

Citations

38

H-Index

YearCitations

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study

Yi‐Long Wu, Caicun Zhou, Chong Kin Liam,

Annals of Oncology

2015

726

Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study

Wen‐Zhao Zhong, Qun Wang, Weimin Mao,

The Lancet Oncology

2017

520

Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial

Wen‐Zhao Zhong, Qun Wang, Weimin Mao,

Journal of Clinical Oncology

2020

261

Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)

Baohui Han, Kai Li, Yizhuo Zhao,

British Journal of Cancer

2018

260

Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG–0803)

Yi‐Long Wu, Caicun Zhou, Ying Cheng,

Annals of Oncology

2012

236

Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial

Li Zhang, Shenglin Ma, Xiangqun Song,

The Lancet Oncology

2012

225

Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study

Qing Zhou, Chong‐Rui Xu, Ying Cheng,

Cancer Cell

2021

220

Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial

Zhijie Wang, Ying Cheng, Tongtong An,

The Lancet Respiratory Medicine

2018

214

Icotinib versus whole-brain irradiation in patients with EGFR -mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial

Jin‐Ji Yang, Caicun Zhou, Yi-Sheng Huang,

The Lancet Respiratory Medicine

2017

183

Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)

Zhijie Wang, Lin Wu, Baolan Li,

Journal of Clinical Oncology

2022

161

Page 1